These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 31429779)

  • 21. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
    Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inhibitory receptor CD94/NKG2A on CD8
    Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
    Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct genomic features across cytolytic subgroups in skin melanoma.
    Roufas C; Georgakopoulos-Soares I; Zaravinos A
    Cancer Immunol Immunother; 2021 Nov; 70(11):3137-3154. PubMed ID: 33779796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
    Thibaudin M; Limagne E; Hampe L; Ballot E; Truntzer C; Ghiringhelli F
    Cancer Immunol Immunother; 2022 Oct; 71(10):2549-2563. PubMed ID: 35292828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.
    Yomoda T; Sudo T; Kawahara A; Shigaki T; Shimomura S; Tajiri K; Nagasu S; Fujita F; Kinugasa T; Akagi Y
    Ann Surg Oncol; 2019 Feb; 26(2):415-424. PubMed ID: 30569297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
    Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
    J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment.
    Shahin M; Patra S; Purkait S; Kar M; Das Majumdar SK; Mishra TS; Samal SC; Nayak HK
    J Gastrointest Cancer; 2024 Jun; 55(2):940-949. PubMed ID: 38530597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis.
    Roufas C; Georgakopoulos-Soares I; Zaravinos A
    NAR Cancer; 2021 Mar; 3(1):zcab005. PubMed ID: 34316699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
    Srivastava P; Husain N; Shukla S; Chauhan S; Pandey A; Masood S
    Indian J Pathol Microbiol; 2021; 64(3):490-496. PubMed ID: 34341259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.
    Mo S; Ma X; Li Y; Zhang L; Hou T; Han-Zhang H; Qian J; Cai S; Huang D; Peng J
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
    Pfuderer PL; Ballhausen A; Seidler F; Stark HJ; Grabe N; Frayling IM; Ager A; von Knebel Doeberitz M; Kloor M; Ahadova A
    Br J Cancer; 2019 Aug; 121(5):395-404. PubMed ID: 31358939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.